Pomalidomide, Cyclophosphamide and Dexamethasone, for the treatment or relapse and refractory multiple myeloma: Real-World analysis of the Pethema-GEM experience.

Abstract Treatment of relapse and refractory multiple myeloma (RRMM) is highly challenging, especially for patients becoming refractory to initial therapy and in particular for patients developing refractoriness to lenalidomide. Indeed, with current approved treatments, median progression-free survival in lenalidomide refractory patients is less than 10 months, reflecting the difficulty in treating this population of patients. Pomalidomide, is a second-generation immunomodulatory drug that has shown activity in lenalidomide refractory patients in the setting of different combinations. Here we report the results of a real-world study conducted by the Spanish Myeloma group in a cohort of patients with RRMM treated with pomalidomide-cyclophosphamide and dexamethasone (PomCiDex). A total of 100 patients were treated with a median of 3 prior lines of therapy. Overall response rate was 39% with a clinical benefit rate of 93%. Median progression-free survival was 7.6m and median overall survival was 12.6m. Median progression-free and overall survival were consistent across the different subgroups analyzed. Prolonged progression-free and overall survival were found in responding patients. Results here published compared favorably with those obtained with different Pomalidomide based combinations in a similar patient population. In conclusion, PomCiDex remains a manageable, cost-effective and all oral triplet combination for RRMM patients.